Sumo-2/3-ylation following in vitro modeled ischemia is reduced in delayed ischemic tolerance

Brain Res. 2009 May 26;1272:71-80. doi: 10.1016/j.brainres.2009.03.034. Epub 2009 Mar 28.

Abstract

Several recent studies suggest that sumo-2/3 modification of proteins occurs following harmful ischemia, however, sumo-2/3-ylation may also be associated with hibernation-mediated neuroprotection. Here we investigate the sumoylation of proteins following ischemia and ischemic tolerance using our established in vitro model of ischemia (oxygen and glucose deprivation; OGD). Following harmful ischemia (120 min OGD), we observed a significant increase in the sumo-2/3-ylation of high molecular weight proteins (>85 kDa), but not sumo-1-ylation of proteins. Sumo-2/3-ylation following 120 min OGD was reduced when cultures were preconditioned with non-harmful 30 min OGD 24 h earlier (delayed ischemic tolerance). However, we observed no change in sumo-2/3-ylation in a model of rapid ischemic tolerance. The effects of preconditioning on sumo-2/3-ylation following harmful ischemia were blocked by the protein synthesis inhibitor cycloheximide (1.0 muM), a known inhibitor of delayed ischemic tolerance. In addition, we observed a reduction in sumo-2/3-ylation using hypothermia (4 degrees C 30 min) as the preconditioning stimuli to induce delayed ischemic tolerance. Further studies show that sumo-2/3-ylation occurs during the ischemic insult and that preconditioning does not change expression of the sumo E1- and E2-ligases (UBA2 and Ubc9) or the sumo specific isopeptidases (SenP1-3). While sumo-2/3-ylation is enhanced under conditions of cell stress, it is not yet clear whether this is a cause or consequence of harmful ischemia-induced cell damage.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Analysis of Variance
  • Animals
  • Animals, Newborn
  • Cells, Cultured
  • Cerebral Cortex / cytology
  • Cycloheximide / pharmacology
  • Down-Regulation / drug effects
  • Down-Regulation / physiology*
  • Glucose / deficiency
  • Hyperthermia, Induced / methods
  • Hypoxia / metabolism
  • Ischemic Preconditioning / methods
  • L-Lactate Dehydrogenase / metabolism
  • Neurons / drug effects
  • Neurons / metabolism*
  • Protein Synthesis Inhibitors / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Small Ubiquitin-Related Modifier Proteins / metabolism*
  • Time Factors

Substances

  • Protein Synthesis Inhibitors
  • SUMO2 protein, rat
  • Small Ubiquitin-Related Modifier Proteins
  • Cycloheximide
  • L-Lactate Dehydrogenase
  • Glucose